Payment overview · 2025
General Payments
$3,216.22
54 reported records · 24 companies
Healthcare provider profile · identity verified
Shawn Michael Poole, MD
Allopathic & Osteopathic Physicians|Surgery|Vascular Surgery · SPRINGFIELD, IL · NPI 1497315873
Verified facts
What the public records show
CMS Open Payments records show Shawn Michael Poole, MD received $3,216.22 in general payments during 2025 across 54 reported records.
Shockwave Medical, Inc accounted for 16.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $545.30 | 16.9% | 6 | 2025 |
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $460.56 | 14.3% | 7 | 2025 |
| ARGON MEDICAL DEVICES, INC. | Unresolved — no canonical attribution shown | $454.34 | 14.1% | 5 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $376.92 | 11.7% | 4 | 2025 |
| Kerecis Limited | Unresolved — no canonical attribution shown | $347.06 | 10.8% | 5 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$316.04 | 9.8% | 5 | 2025 |
| Access Pro Medical, LLC | Unresolved — no canonical attribution shown | $142.28 | 4.4% | 2 | 2025 |
| Aroa Biosurgery Incorporated | Unresolved — no canonical attribution shown | $94.51 | 2.9% | 1 | 2025 |
| Surmodics, Inc. | Unresolved — no canonical attribution shown | $61.59 | 1.9% | 1 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $52.59 | 1.6% | 2 | 2025 |
| Bard Peripheral Vascular, Inc. | Unresolved — no canonical attribution shown | $50.93 | 1.6% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $42.92 | 1.3% | 2 | 2025 |
| Imperative Care, Inc | Unresolved — no canonical attribution shown | $31.90 | 1.0% | 1 | 2025 |
| PolyNovo North America LLC | Unresolved — no canonical attribution shown | $31.43 | 1.0% | 1 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $27.79 | 0.9% | 1 | 2025 |
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $23.40 | 0.7% | 1 | 2025 |
| Stimlabs LLC | Unresolved — no canonical attribution shown | $22.31 | 0.7% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $21.65 | 0.7% | 1 | 2025 |
| Humacyte Global, Inc. | Unresolved — no canonical attribution shown | $21.49 | 0.7% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $20.39 | 0.6% | 1 | 2025 |
| Acera Surgical, Inc. | Unresolved — no canonical attribution shown | $20.04 | 0.6% | 1 | 2025 |
| MIMEDX Group, Inc. | Unresolved — no canonical attribution shown | $18.07 | 0.6% | 1 | 2025 |
| LeMaitre Vascular, Inc. | Unresolved — no canonical attribution shown | $17.77 | 0.6% | 1 | 2025 |
| Molnlycke Health Care US, LLC | Unresolved — no canonical attribution shown | $14.94 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,166.22 | 53 |
| Education | $50.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $545.30 | 6 | 2025 |
Source payment records
|
|||||
| CLOT MANAGEMENT Normalized: clot management |
Device | ARGON MEDICAL DEVICES, INC. | $454.34 | 5 | 2025 |
Source payment records
|
|||||
| GORE VIABAHN Endoprosthesis Normalized: gore viabahn endoprosthesis |
Device | W. L. Gore & Associates, Inc. | $360.14 | 4 | 2025 |
Source payment records
|
|||||
| Kerecis GraftGuide Normalized: kerecis graftguide |
Device | Kerecis Limited | $347.06 | 5 | 2025 |
Source payment records
|
|||||
| Kerecis SurgiClose Normalized: kerecis surgiclose |
Device | Kerecis Limited | $347.06 | 5 | 2025 |
Source payment records
|
|||||
| HAWKONE Normalized: hawkone |
Device | Medtronic, Inc. | $279.85 | 4 | 2025 |
Source payment records
|
|||||
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $225.54 | 3 | 2025 |
Source payment records
|
|||||
| Penumbra System Normalized: penumbra system |
Device | Penumbra, Inc. | $151.38 | 1 | 2025 |
Source payment records
|
|||||
| MATRIDERM Normalized: matriderm |
Device | Access Pro Medical, LLC | $142.28 | 2 | 2025 |
Source payment records
|
|||||
| Pounce Thrombectomy Normalized: pounce thrombectomy |
Device | Surmodics, Inc. | $61.59 | 1 | 2025 |
Source payment records
|
|||||
| Pounce Venous Thrombectomy System Normalized: pounce venous thrombectomy system |
Device | Surmodics, Inc. | $61.59 | 1 | 2025 |
Source payment records
|
|||||
| GORE-TEX Vascular Graft Normalized: gore tex vascular graft |
Device | W. L. Gore & Associates, Inc. | $50.00 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $42.92 | 2 | 2025 |
Source payment records
|
|||||
| ABRE Normalized: abre |
Device | Medtronic, Inc. | $36.19 | 1 | 2025 |
Source payment records
|
|||||
| SYMPHONY CATHETER Normalized: symphony catheter |
Device | Imperative Care, Inc | $31.90 | 1 | 2025 |
Source payment records
|
|||||
| NOVOSORB BTM Normalized: novosorb btm |
Device | PolyNovo North America LLC | $31.43 | 1 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Stryker Corporation | $28.96 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Stryker Corporation | $28.96 | 1 | 2025 |
Source payment records
|
|||||
| COVERA Normalized: covera |
Device | Bard Peripheral Vascular, Inc. | $28.43 | 1 | 2025 |
Source payment records
|
|||||
| FLOSEAL Normalized: floseal |
Biological | Baxter Healthcare | $27.79 | 1 | 2025 |
Source payment records
|
|||||
| GORE VIABAHN Endoprosthesis with Heparin Normalized: gore viabahn endoprosthesis with heparin |
Device | W. L. Gore & Associates, Inc. | $25.73 | 1 | 2025 |
Source payment records
|
|||||
| GORE PROPATEN Vascular Graft Normalized: gore propaten vascular graft |
Device | W. L. Gore & Associates, Inc. | $24.69 | 1 | 2025 |
Source payment records
|
|||||
| ARTIX MT Normalized: artix mt |
Device | Stryker Corporation | $23.63 | 1 | 2025 |
Source payment records
|
|||||
| AURYON LASER SYSTEM 100-120 VAC Normalized: auryon laser system 100 120 vac |
Device | AngioDynamics, Inc. | $23.40 | 1 | 2025 |
Source payment records
|
|||||
| Venovo Normalized: venovo |
Device | Bard Peripheral Vascular, Inc. | $22.50 | 1 | 2025 |
Source payment records
|
|||||
| CORPLEX P Normalized: corplex p |
Device | Stimlabs LLC | $22.31 | 1 | 2025 |
Source payment records
|
|||||
| Visions 014 Normalized: visions 014 |
Device | Philips North America LLC | $21.65 | 1 | 2025 |
Source payment records
|
|||||
| Symvess Normalized: symvess |
Biological | Humacyte Global, Inc. | $21.49 | 1 | 2025 |
Source payment records
|
|||||
| Varithena Administration Pack Normalized: varithena administration pack |
Device | Boston Scientific Corporation | $20.39 | 1 | 2025 |
Source payment records
|
|||||
| Restrata Wound Matrix Normalized: restrata wound matrix |
Device | Acera Surgical, Inc. | $20.04 | 1 | 2025 |
Source payment records
|
|||||
| ARTEGRAFT VASCULAR GRAFT Normalized: artegraft vascular graft |
Device | LeMaitre Vascular, Inc. | $17.77 | 1 | 2025 |
Source payment records
|
|||||
| Mepilex Border Post-Op Ag Normalized: mepilex border post op ag |
Device | Molnlycke Health Care US, LLC | $14.94 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clopidogrel | Clopidogrel Bisulfate | 18 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,216.22 · 54 records | Shockwave Medical, Inc | ABRE, ARTEGRAFT VASCULAR GRAFT, ARTIX MT, AURYON LASER SYSTEM 100-120 VAC, CLOT MANAGEMENT, CORPLEX P, COVERA, CT THROMBECTOMY SYSTEM KIT, ELIQUIS, FLOSEAL, FLOWTRIEVER CATHETER, S, GORE PROPATEN Vascular Graft, GORE VIABAHN Endoprosthesis, GORE VIABAHN Endoprosthesis with Heparin, GORE-TEX Vascular Graft, HAWKONE, Indigo System, Kerecis GraftGuide, Kerecis SurgiClose, MATRIDERM, Mepilex Border Post-Op Ag, NOVOSORB BTM, Penumbra System, Pounce Thrombectomy, Pounce Venous Thrombectomy System, Restrata Wound Matrix, SYMPHONY CATHETER, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, Symvess, Varithena Administration Pack, Venovo, Visions 014 | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error